{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:25:51Z","timestamp":1760145951128,"version":"build-2065373602"},"reference-count":63,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Adult T-cell Leukemia\/Lymphoma (ATLL) is a rare but aggressive malignancy associated with the human T-cell lymphotropic virus type 1 (HTLV-1). ATLL is a challenging malignancy characterized by its aggressive nature and poor prognosis. Despite advancements in treatment, relapse rates remain high. Donor lymphocyte infusion (DLI) is a promising therapeutic option post-hematopoietic stem cell transplantation (HSCT) to prevent relapse. However, the prophylactic use of DLI in ATLL patients remains underexplored. We report the case of a 45-year-old female diagnosed with ATLL. Following induction chemotherapy and successful HSCT, a modified prophylactic DLI regimen was administered, consisting of gradually increasing doses of donor lymphocytes. The patient demonstrated a favorable response with no significant graft-versus-host disease (GVHD) and maintained remission over a 40-month follow-up period, suggesting a potential benefit of this approach. This case highlights the potential efficacy and safety of modified prophylactic DLI in ATLL patients, warranting further investigation. Our findings suggest that modified prophylactic DLI is a viable option for ATLL patients post-HSCT, offering a balance between efficacy and safety. Future research should focus on optimizing DLI protocols and exploring biomarkers for response prediction.<\/jats:p>","DOI":"10.3390\/diseases12090210","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T05:45:12Z","timestamp":1726033512000},"page":"210","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modified Prophylactic Donor Lymphocyte Infusion (DLI) in an Adult T Cell Lymphoma\/Leukemia (ATLL) Patient\u2014Modality of Relapse Prevention"],"prefix":"10.3390","volume":"12","author":[{"given":"Alexandra","family":"Ionete","sequence":"first","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Faculty of General Medicine, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Bardas","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Faculty of General Medicine, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsofia","family":"Varady","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madalina","family":"Vasilica","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Szegedi","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-6079","authenticated-orcid":false,"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Faculty of General Medicine, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","article-title":"Global epidemiology of HTLV-I infection and associated diseases","volume":"24","author":"Proietti","year":"2005","journal-title":"Oncogene"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gessain, A., and Cassar, O. (2012). Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front. Microbiol., 3.","DOI":"10.3389\/fmicb.2012.00388"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.1994.tb01297.x","article-title":"HTLV-I in Romania","volume":"52","author":"Paun","year":"1994","journal-title":"Eur. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1423-0410.2008.01136.x","article-title":"Blood safety strategies for human T-cell lymphotropic virus in Europe","volume":"96","author":"Laperche","year":"2009","journal-title":"Vox Sang."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/0140-6736(90)90466-I","article-title":"HIV-1 infection in Romanian children","volume":"335","author":"Patrascu","year":"1990","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0042-6822(91)90418-B","article-title":"HTLV-1 envelope sequences from Brazil, the Caribbean, and Romania: Clustering of sequences according to geographic origin and variability in an antibody epitope","volume":"184","author":"Schulz","year":"1991","journal-title":"Virology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1182\/blood-2019-126434","article-title":"Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence","volume":"134","author":"Bumbea","year":"2019","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bmt.2014.143","article-title":"Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: A retrospective study by the EBMT LWP","volume":"49","author":"Bazarbachi","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tanase, A.D., Colita, A., Craciun, O.G., Lipan, L., Varady, Z., Stefan, L., Ranete, A., Pasca, S., Bumbea, H., and Andreescu, M. (2020). Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia\/Lymphoma\u2014Romanian Experience. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082417"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"ref_11","first-page":"979","article-title":"Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation","volume":"15","author":"Pati","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT","volume":"105","author":"Dholaria","year":"2019","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ijc.31753","article-title":"Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders","volume":"144","author":"Hofmann","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.bbmt.2018.03.030","article-title":"Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT","volume":"24","author":"Liu","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2013.02.005","article-title":"Finding the Sweet Spot for Donor Lymphocyte Infusions","volume":"19","author":"Yun","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2010.05.005","article-title":"NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies","volume":"16","author":"Alyea","year":"2010","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donorlymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","first-page":"4","article-title":"Proceedings from the National Cancer Institute\u2019s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation","volume":"20","author":"Porter","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/asheducation-2017.1.708","article-title":"Cells to prevent\/treat relapse following allogeneic stem cell transplantation","volume":"2017","author":"Dietz","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1182\/blood-2015-12-629089","article-title":"Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies","volume":"127","author":"Sun","year":"2016","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2010.08.031","article-title":"Natural Killer Cell Education and Tolerance","volume":"142","author":"Orr","year":"2010","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2017-08-752162","article-title":"The potential role of \u03b3\u03b4 T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","article-title":"Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation","volume":"20","author":"Takami","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bbmt.2017.02.012","article-title":"Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program","volume":"23","author":"Miyamoto","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbmt.2014.10.010","article-title":"Outcomes of Donor Lymphocyte Infusion for Treatment of Mixed Donor Chimerism after a Reduced-Intensity Preparative Regimen for Pediatric Patients with Nonmalignant Diseases","volume":"21","author":"Haines","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbmt.2012.07.021","article-title":"High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen","volume":"19","author":"Liga","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41409-019-0597-y","article-title":"T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease","volume":"54","author":"Pierini","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.10570","article-title":"Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation","volume":"92","author":"Huang","year":"2007","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41409-020-01088-7","article-title":"Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: A matched-pair analysis","volume":"56","author":"Yang","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/ejh.12168","article-title":"Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: Superior outcomes compared with chemotherapy alone and an analysis of prognostic factors","volume":"91","author":"Yan","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-016-0319-5","article-title":"Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant","volume":"9","author":"Yan","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbmt.2017.04.028","article-title":"Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease\u2013Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory\/Relapsed Acute Leukemia","volume":"23","author":"Yan","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/bmt.2016.326","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML","volume":"52","author":"Legrand","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s11427-019-9597-3","article-title":"Modification of donor lymphocyte infusion: How to improve the outcome?","volume":"62","author":"Wang","year":"2019","journal-title":"Sci. China Life Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.trim.2006.10.002","article-title":"Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions","volume":"17","author":"Huang","year":"2007","journal-title":"Transpl. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1532\/IJH97.A10227","article-title":"Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on T-Lymphocyte Function and the Mechanism of This Effect","volume":"79","author":"Chen","year":"2004","journal-title":"Int. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15881","article-title":"G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients","volume":"186","author":"Schneidawind","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbmt.2008.11.027","article-title":"Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin\u00ae) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation","volume":"15","author":"Call","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","article-title":"Treatment of Adult T-Cell Leukemia\u2013Lymphoma with a Combination of Interferon Alfa and Zidovudine","volume":"332","author":"Gill","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","article-title":"Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa","volume":"332","author":"Hermine","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1097\/00042560-199600001-00028","article-title":"Treatment with a Combination of Zidovudine and \u03b1-Interferon in Naive and Pretreated Adult T-Cell Leukemia\/Lymphoma Patients","volume":"13","author":"Bazarbachi","year":"1996","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM199511093331911","article-title":"Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma. Lymphoma Study Group of the Japan Clinical Oncology Group","volume":"333","author":"Tobinai","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.2001.02794.x","article-title":"Interferon \u03b1 and zidovudine therapy in adult T-cell leukaemia lymphoma: Response and outcome in 15 patients","volume":"113","author":"Matutes","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_48","first-page":"276","article-title":"A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma","volume":"3","author":"Hermine","year":"2002","journal-title":"Hematol. J. Off. J. Eur. Haematol. Assoc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia\/Lymphoma Showing Improved Survival in the Leukemic Subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1200\/JCO.2011.35.5578","article-title":"Use of Zidovudine and Interferon Alfa with Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia\/Lymphoma","volume":"29","author":"Hodson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bmt.2015.265","article-title":"Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma","volume":"51","author":"Fuji","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303","volume":"113","author":"Yamada","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3324\/haematol.2017.164996","article-title":"Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: Possible risk-adapted management strategies including allogeneic transplantation","volume":"102","author":"Fuji","year":"2017","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia\/Lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1056\/NEJMc053295","article-title":"Donor-Derived T-Cell Leukemia after Bone Marrow Transplantation","volume":"354","author":"Tamaki","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2004-11-4193","article-title":"Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma","volume":"105","author":"Okamura","year":"2005","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bbmt.2008.03.010","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning for Adult T Cell Leukemia\/Lymphoma: Impact of Antithymocyte Globulin on Clinical Outcome","volume":"14","author":"Tanosaki","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bmt.2010.92","article-title":"Long-term outcomes after hematopoietic SCT for adult T-cell leukemia\/lymphoma: Results of prospective trials","volume":"46","author":"Choi","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hon.2558","article-title":"The outcome and characteristics of patients with relapsed adult T cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Kato","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2012-07-444372","article-title":"Treatment of relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki Transplant Group experience","volume":"121","author":"Itonaga","year":"2013","journal-title":"Blood"},{"key":"ref_61","first-page":"505","article-title":"Treatment approach for relapse of adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation","volume":"62","author":"Kato","year":"2021","journal-title":"Rinsho Ketsueki"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12185-023-03595-x","article-title":"Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation","volume":"118","author":"Harada","year":"2023","journal-title":"Int. J. Hematol."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/9\/210\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:53:44Z","timestamp":1760111624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/9\/210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":63,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["diseases12090210"],"URL":"https:\/\/doi.org\/10.3390\/diseases12090210","relation":{},"ISSN":["2079-9721"],"issn-type":[{"type":"electronic","value":"2079-9721"}],"subject":[],"published":{"date-parts":[[2024,9,11]]}}}